Navigation Links
Sigma-Aldrich (Nasdaq: SIAL) Reports Q4 and Full Year 2010 Diluted EPS of $0.76 and $3.12, Respectively. Q4 and Full Year 2010 Adjusted Diluted EPS Were $0.83 and $3.31, Respectively. Q4 Sales Set New Quarterly High. 2011 Diluted EPS Expected to be
Date:2/9/2011

ST. LOUIS, Feb. 9, 2011 /PRNewswire/ --

HIGHLIGHTS:2010 Results (all percentages are to comparable periods in 2009)

  • Q4 2010 reported sales were $582 million, a new quarterly high. Q4 sales grew by 2% and 3% on a reported and currency adjusted basis, respectively.  Full year 2010 sales increased 6% and 5% on a reported and currency adjusted basis, respectively.  
  • Q4 2010 reported diluted EPS was $0.76. Excluding restructuring costs of $0.07, adjusted Q4 2010 diluted EPS was $0.83, up 4%. Full year 2010 reported EPS was $3.12. Excluding $0.19 of restructuring and impairment costs, 2010 adjusted diluted EPS was $3.31, a 16% increase over 2009's adjusted diluted EPS.  
  • Full year 2010 net cash provided by operating activities was $523 million and free cash flow was $424 million.

  • 2011 Outlook (all percentages are compared to full year 2010 results)

  • Sales for the full year are expected to increase in a mid-single digit range, with market conditions similar to 2010. Sales growth is not likely to be significantly impacted if currency exchange rates remain near current levels.
  • Diluted adjusted EPS forecast (excluding restructuring or other extraordinary special charges) is expected to be $3.45 to $3.60, a 4% to 9% increase over 2010's adjusted EPS.  See 2011 Outlook below.
  • Net cash provided by operating activities is expected to exceed $500 million. Free cash flow is expected to exceed $375 million.  

  • DividendAt a meeting held on February 8, 2011, the Directors increased the Company's quarterly cash dividend by 12.5% to $0.18 per share.  The dividend is payable on March 15, 2011 to shareholders of record on March 1, 2011.   CEO's STATEMENT:Commenting on the fourth quarter of 2010, President and CEO Rakesh Sachdev said:  "The fourth quarter was marked with the tragic loss of our long-time colleagu
    '/>"/>

    SOURCE Sigma-Aldrich
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

    Related biology technology :

    1. Sigma-Aldrich to Present at the JP Morgan 29th Annual Healthcare Conference on Monday, January 10, 2011.
    2. Sigma-Aldrich Acquires Cerilliant Corporation to Strengthen its Analytical Chemistry Portfolio
    3. Sigma-Aldrich Corporation Announces Death of Chairman and CEO; Election of New CEO and Chairman; Conference Call Scheduled for 10:00a.m. (Central Time) on November 15, 2010
    4. Sigma-Aldrich Announces Pricing of Senior Notes
    5. Sigma-Aldrich (Nasdaq: SIAL) Reports Q3 2010 Diluted EPS of $0.76. Diluted EPS Increased by 9% and 19% on a Reported and Adjusted Basis, Respectively. Q3 Sales Performance Remains Strong; Full Year 2010 Diluted Adjusted EPS Outlook Raised to $3.20 -
    6. Sigma-Aldrich to Present at the UBS Global Life Sciences Healthcare Conference on Tuesday, September 21, 2010
    7. Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO)
    8. Sigma-Aldrich Corporation to Present at the Bairds 2010 Growth Stock Conference on Thursday, May 20, 2010
    9. Sigma-Aldrich (Nasdaq: SIAL) Announces Executive Management Changes: Retirement of David Julien and Promotion of Joseph Porwoll
    10. Sigma-Aldrich to Present at the Bank of America Merrill Lynch 2010 Health Care Conference on Wednesday, May 12, 2010
    11. Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2015)... -- China Cord Blood Corporation (NYSE: CO) ("CCBC" or ... of cord blood collection, laboratory testing, hematopoietic stem cell ... the Company has filed its Annual Report on Form ... filed Form 20-F includes audited financial statements for the ... can be accessed by visiting the U.S. Securities and ...
    (Date:7/30/2015)... CAMBRIDGE, Mass. , July 30, 2015 /PRNewswire/ ... software solutions for the interpretation and analysis of ... Matthew Fischer has joined the company ... Photo - http://photos.prnewswire.com/prnh/20150730/250931 ... astounding capabilities to integrate, interpret, analyze and explore ...
    (Date:7/30/2015)... ... July 30, 2015 , ... ... field clinical study of its canine osteoarthritis stem cell product, currently under development ... City, KS) and will be marketed in the US by Aratana. This product, ...
    (Date:7/30/2015)... Ascendis Pharma A/S (Nasdaq: ASND ... TransCon technology to address significant unmet medical needs, ... Phase 2 study to evaluate the safety and ... treatment-naïve, pre-pubertal children with growth hormone deficiency, or ... the top-line results from our Phase 2 pediatric ...
    Breaking Biology Technology:China Cord Blood Corporation Files Its Annual Report on Form 20-F 2GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
    ... hurdle using Star-P, WALTHAM, Mass., Feb. ... Architecture Research Lab (NUCAR) and the National,Science ... Imaging,Systems (CenSSIS) are teaming with Massachusetts General ... detection technology that improves breast,cancer screening accuracy. ...
    ... (Nasdaq: NPSP ) announced today that Dr. Tony ... chief executive,officer and a director effective March 17, 2008 ... Onyx Pharmaceuticals, Inc. (Nasdaq:,ONXX). He will be succeeded by ... Nader, who will become president and chief,executive officer of ...
    ... (OTC,Bulletin Board: SNKTY), a Life Sciences company engaged in ... aging, today announced,that results of a clinical study of ... Journal of Drugs in Dermatology., The study was ... over 12 weeks for improving the baseline clinical,signs and ...
    Cached Biology Technology:Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 2Northeastern University and Mass General Hospital Increase the Accuracy, While Reducing the Diagnosis Time, for Breast Cancer Detection 3NPS Pharmaceuticals Announces Senior Management Changes 2NPS Pharmaceuticals Announces Senior Management Changes 3Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 2Pyratine-6(TM) Study Published in Journal of Drugs in Dermatology 3
    (Date:7/31/2015)... 31 juillet 2015 La 10e Conférence ... sera organisée par le BGI du 22 au ... en Chine. La conférence célèbre ... en 2006, l,ICG est devenue l,une des réunions ... des « omiques » et c,est aussi la plus dynamique, ...
    (Date:7/31/2015)... Jul. 31, 2015 NXT-ID, Inc. (NASDAQ: NXTD ... focused on the growing mobile commerce market and creator ... filed provisional patent 62/198989 for ELECTRONIC CRYPTO-CURRENCY ... a method to advance crypto-currencies such as Bitcoin into ... common, uniform way to manage all payments.  ...
    (Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
    Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3
    ... two-dozen countries have signed a consensus statement on the ... as the most serious and pervasive include overfishing, pollution, ... "This is first time the scientific ... express urgency over the environmental crisis facing the Pacific ...
    ... feeding frenzy that played out 73 million years ago ... of new dinosaur species in northwestern Alberta. University ... paleontology graduate student from Italy, made the discovery near ... Miyashita and Fanti came across a nesting site and ...
    ... Rare traits persist in a population because predators detect common ... access journal BMC Ecology found that birds will ... their behavior in response to alterations in the ratio of ... of Tennessee, worked with Kim Shook and Reuben Izally to ...
    Cached Biology News:Scientists urge world leaders to respond cooperatively to Pacific Ocean threats 2New dinosaur species possible in Northwestern Alberta 2
    The LIC Duet™ Mini Adaptor encodes a T7 promoter, lac operator, ribosome binding site (rbs), and an ATG translation initation codon. This adaptor is designed for expression of a target protei...
    ... scale-up, these culture chambers produce cell yields ... range and are useful alternatives to ... High mechanical • strength and structural integrity ... • Certified nonpyrogenic and sterilized by gamma ...
    ABgene® supplies a 94kDa ultra-pure recombinant thermostable DNA polymerase obtained by high level expression of the Taq DNA polymerase gene in E. coli....
    ...
    Biology Products: